Holen Sie sich die Stockscreener-App
25.85
2.60%
0.51
Schlusskurs vom Vortag:
$25.34
Offen:
$25.72
24-Stunden-Volumen:
1,451
Relative Volume:
0.01
Marktkapitalisierung:
$1.69B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-180.80M
KGV:
-8.0342
EPS:
-3.2175
Netto-Cashflow:
$-150.76M
1W Leistung:
-0.65%
1M Leistung:
-5.90%
6M Leistung:
+5.78%
1J Leistung:
+70.49%
1-Tages-Spanne:
$25.72
$25.98
1-Wochen-Bereich:
$24.95
$27.13
52-Wochen-Spanne:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
25.98 | 1.65B | 0 | -180.80M | -150.76M | -3.2175 |
VRTX
Vertex Pharmaceuticals Inc
|
450.52 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.15 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
689.30 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.99 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
281.94 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
PHVS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing - Stock Traders Daily
PHVS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Lancet publishes Phase 2 oral treatment data for rare swelling disorder - Stock Titan
Guggenheim maintains Pharvaris NV (PHVS) buy recommendation - MSN
[Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership - Stock Titan
Pharvaris (PHVS) director Glassman reports stock options and RSU holdings - Stock Titan
Pharvaris (PHVS) director discloses sizable stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) director details options, RSUs and shares - Stock Titan
Pharvaris (PHVS) CFO discloses common stock and option holdings - Stock Titan
Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings - Stock Titan
Pharvaris (PHVS) CCO reports initial stock, RSU and option holdings - Stock Titan
Pharvaris (PHVS) PAO reports initial share, option and RSU holdings - Stock Titan
Pharvaris (PHVS) director David Meeker reports stock, options and RSUs - Stock Titan
Pharvaris (PHVS) director Viviane Monges details initial equity holdings - Stock Titan
Pharvaris (PHVS) CMO Lu Peng details initial share and stock option holdings - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig details stock, RSUs and options - Stock Titan
Pharvaris (PHVS) CHRO details option and RSU equity holdings - Stock Titan
Is New HAE Patient-Reported Outcome Study Altering The Investment Case For Pharvaris’ Deucrictibant (PHVS)? - simplywall.st
Trend Recap: How sensitive is Pharvaris NV to inflation2026 Risk Factors & Long Hold Capital Preservation Tips - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After New Real‑World HAE Study Supports Deucrictibant Trials - Sahm
Patient attack ratings to guide Pharvaris hereditary angioedema trials - Stock Titan
PHVS: Oral therapies for angioedema show strong data, with launches and key filings expected by 2027 - TradingView
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Royal Bank Of Canada - Defense World
Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage? - simplywall.st
(PHVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
PHVS Should I Buy - Intellectia AI
Pharvaris N.V. (PHVS) Presents at American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual MeetingSlideshow (NASDAQ:PHVS) 2026-03-05 - Seeking Alpha
Portfolio Recap: Does Pharvaris NV stock have upside surprise potentialQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Pharvaris shares slide following $175 million equity offering - MSN
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
PHVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):